Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized Trial of Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) Versus Adebrelimab Combined With TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of Triple-negative Breast Cancer

NCT06165900 is registered in ClinicalTrials.gov with Shengjing Hospital as lead sponsor.

NCT NCT06165900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06165900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized Trial of Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) Versus Adebrelimab Combined With TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of Triple-negative Breast Cancer
Lead sponsor
Shengjing Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
September 26, 2023
Completion date
December 15, 2028
Enrollment
136 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, immunotherapy, stereotactic radiotherapy